english.prescrire.org > Spotlight > 100 most recent > Cabotegravir (Apretude°) in HIV pre-exposure prophylaxis (PrEP)

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Cabotegravir (Apretude°) in HIV pre-exposure prophylaxis (PrEP)

 Marketing Authorisations  Cabotegravir, an HIV integrase inhibitor, administered by intramuscular injection, is already authorised in the European Union under the brand name Vocabria° for use in combination with rilpivirine in HIV-infected patients. It is now also authorised as monotherapy under the brand name Apretude°.
Full article available for download by subscribers

 ©Prescrire 1 May 2025

Source: "Cabotegravir (Apretude°) in HIV pre-exposure prophylaxis (PrEP)" Prescrire Int 2025; 34 (270): 120-121. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:

"Cabotegravir (Vocabria°)
and rilpivirine (Rekambys°)
IM injections in HIV infection.
An alternative to oral two-drug
regimens"
Prescrire Int 2022;
31 (236): 94-95.
Subscribers only